Researchers at The Institute of Cancer Research, London identified the CIP2A–TOPBP1 complex as a master regulator of DNA ...

The review emphasizes how breakthroughs in understanding the molecular mechanisms of cell cycle regulation have paved the way for the development of targeted anti-cancer agents. Notably, inhibitors of ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

Understanding why cancer cells rely on specific genes is critical for designing effective targeted therapies. A new study ...

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...

“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...

Rb1 loss may serve as a predictive biomarker to guide new targeted therapies for select breast cancers resistant to standard ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people ...